Antimicrobial use and combination of resistance phenotypes in bacteraemic Escherichia coli in primary care: a study based on Japanese national data in 2018

• Published in: Journal of antimicrobial chemotherapy 2024-02, Vol.79 (2), p.312-319
• Main Authors: Hosaka, Yumiko, Muraki, Yuichi, Kajihara, Toshiki, Kawakami, Sayoko, Hirabayashi, Aki, Shimojima, Masahiro, Ohge, Hiroki, Sugai, Motoyuki, Yahara, Koji
• Format: Article
• Language: English
• Subjects: Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Anti-Infective Agents - pharmacology; Bacteremia - drug therapy; Bacteremia - epidemiology; Cephalosporins - pharmacology; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones - pharmacology; Humans; Japan - epidemiology; Original Research; Primary Health Care
• ISSN: 0305-7453; 1460-2091; 1460-2091
• DOI: 10.1093/jac/dkad379

Abstract Background Antimicrobial use (AMU) in primary care is a contributing factor to the emergence of antimicrobial-resistant bacteria. We assessed the potential effects of AMU on the prevalence of a combination of resistance phenotypes in bacteraemic Escherichia coli in outpatient care settings between primary care facilities (‘clinics’) and hospitals. Methods Population-weighted total AMU calculated from the national database was expressed as DDDs per 1000 inhabitants per day (DID). National data for all routine microbiological test results were exported from the databases of a major commercial clinical laboratory, including 16 484 clinics, and the Japan Nosocomial Infections Surveillance, including 1947 hospitals. AMU and the prevalence of combinations of resistance phenotypes in bacteraemic E. coli isolates were compared between clinics and hospitals. Results The five most common bacteria isolated from patients with bacteraemia were the same in clinics, outpatient settings and inpatient settings in hospitals, with E. coli as the most frequent. Oral third-generation cephalosporins and fluoroquinolones were the top two AMU outpatient drugs, except for macrolides, and resulted in at least three times higher AMU in clinics than in hospitals. The percentage of E. coli isolates resistant to both drugs in clinics (18.7%) was 5.6% higher than that in hospitals (13.1%) (P < 10−8). Conclusions Significant AMU, specifically of oral third-generation cephalosporins and fluoroquinolones, in clinics is associated with a higher prevalence of E. coli isolates resistant to both drugs. This study provides a basis for national interventions to reduce inappropriate AMU in primary care settings.